Completed Projects

Team IMT: Immunosuppressive Microenvironment of Tumors

Solid tumors are complex microenvironments composed of cancer and immune cells that interact through various regulatory networks. Although CD8 T-cells may recognize and kill tumor cells, their function is impaired by cells such as regulatory T-cells, tumor-associated macrophages (TAM), and myeloid-derived suppressor cells (MDSC). The success of the so-called checkpoint blockade strategy and numerous clinical and preclinical studies have demonstrated that alleviating immunosuppression translates into a therapeutic benefit.

Our team is exploring new strategies to relieve immunosuppression and improve anti-tumor response. Current projects focus on the establishment of antibody-discovery platforms, the isolation of specific antibodies, and their functionalization. Furthermore, our group develops platforms that allow investigation into the development and suppressive activity of myeloid cells in both human beings and mice.

Publications

    1. Schröder M, Loos S, Naumann SK, Bachran C, Krötschel M, Umansky V, Helming L, Swee LK.
      Identification of inhibitors of myeloid-derived suppressor cells activity through phenotypic chemical screening. Oncoimmunology. 2016
    2. Bachran C, Schröder M, Conrad L, Cragnolini JJ, Tafesse FG, Helming L, Ploegh HL, Swee LK.
      The activity of myeloid cell-specific VHH immunotoxins is target-, epitope-, subset- and organ dependent. Scientific Reports. 2017
    3. Wöll S, Schiller S, Bachran C, Swee LK, Scherließ R.
      Pentaglycine lipid derivates – rp-HPLC-analytics for bioorthogonal anchor molecules in targeted, multiple-composite liposomal drug delivery systems. Int J Pharm. 2018
The research of this team is kindly sponsored by Merck.
The research of this team was kindly sponsored by Merck.